CI-1020
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


CI-1020
Description :
CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration[1][2][3].Product Name Alternative :
PD156707UNSPSC :
12352005Target :
Endothelin ReceptorType :
Reference compoundRelated Pathways :
GPCR/G ProteinApplications :
Neuroscience-NeuromodulationField of Research :
Cardiovascular DiseaseAssay Protocol :
https://www.medchemexpress.com/ci-1020.htmlSolubility :
10 mM in DMSOSmiles :
O=C1OC(C2=CC=C(OC)C=C2)(O)C(CC3=CC(OC)=C(OC)C(OC)=C3)=C1C4=CC=C(OCO5)C5=C4Molecular Formula :
C28H26O9Molecular Weight :
506.50References & Citations :
[1]Maguire JJ, et al. ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clin Sci (Lond) . 2002 Aug;103 Suppl 48:184S-188S.|[2]Doherty AM, et al. Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Pharm Biotechnol. 1998;11:81-112. |[3]Jones RD, et al. The effect of the endothelin ET (A) receptor antagonist CI-1020 on hypoxic pulmonary vasoconstriction. Eur J Pharmacol. 1999 Jun 25;374 (3) :367-75.|[4]Sheedy W, et al. The effect of the ETA receptor antagonist (CI-1020) in rats with established hypoxic pulmonary hypertension. Pulm Pharmacol Ther. 1998 Apr-Jun;11 (2-3) :173-6.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
ETACAS Number :
[162256-50-0]

